Conversion to everolimus in kidney transplant recipients: To believe or not believe?

Transplantation Proceedings

Volumn 44, Issue 10, 2012, Pages 2966-2970

  Cotovio, P ^a   Neves, M ^a   Santos, L ^a   MacArio F ^a   Alves, R ^a   Mota, A ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUTH ULCER; NEPHROTOXICITY; PANCREATITIS; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; TOXIC HEPATITIS;

ADOLESCENT; ADULT; AGED; CALCINEURIN; CHI-SQUARE DISTRIBUTION; DRUG SUBSTITUTION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870156629     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2012.06.072     Document Type: Article

References (30)

1. S. Sahin, A. Gürkan, M. Uyar Conversion to proliferation signal inhibitors-based immuno-suppressive regimen in kidney transplantation: to whom and when? Transplant Proc 43 2011 837
2. D. Hernández, D. Martínez, E. Gutiérrez Clinical evidence on the use of anti-mTOR drugs in renal transplantation Nefrologia 31 2011 27
3. H. Meier-Kriesche, J. Schold, T. Srinivas Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era Am J Transplant 4 2004 378
4. W. Schuler, R. Sedrani, S. Cottens SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo Transplantation 64 1997 36
5. A. Farb, M. John, E. Acampado Oral everolimus inhibits in-stent neointimal growth Circulation 106 2002 2379
6. R. Waksman, R. Pakala, R. Baffour Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries Cardiovasc Revasc Med 7 2006 179
7. M. Koch, M. Mengel, D. Poehnert Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients Transplantation 83 2007 498
8. H. Holdaas, O. Bentdal, P. Pfeffer Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study Clin Transplant 22 2008 366
9. F.J. Bemelman, E.F. De Maar, R.R. Press Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis Transplantation 88 2009 421
10. L. Rostaing, N. Kamar mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 23 2010 133
11. G. Stallone, B. Infante, A. Schena Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients J Am Soc Nephrol 16 2005 3755
12. B.D. Kahan Rapamune US Study Group Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study Lancet 356 2000 194
13. G. Ciancio, G.W. Burke, J.J. Gaynor A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/ sirolimus in renal transplantation: three year analysis Transplantation 81 2006 845
14. M. Pascual, J. Curtis, F.L. Delmonico A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation Transplantation 75 2003 1501
15. J.M. Grinyo, J.M. Cruzado Mycophenolate mofetil and sirolimus combination in renal transplantation Am J Transplant 6 2006 1991
16. J.C. Ruiz, A. Sánchez, M. Rengel Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry Transplant Proc 39 2007 2157
17. A. Fernández, R. Marcén, C. Galeano Complete switch to everolimus in long-term kidney transplants: evolution of the renal function Transplant Proc 41 2009 2345
18. A. Inza, S. Balda, E. Álvarez Conversion to everolimus in kidney transplant recipients with decreased renal function Transplant Proc 41 2009 2134
19. J. Morales, A. Fierro, D. Benavente Conversion from a calcineurin inhibitor-based immunossupressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria Transplant Proc 39 2007 591
20. E. Sola, V. Lopez, C. Gutierrez Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years Transplant Proc 42 2010 2859
21. J. Lutz, H. Zou, S. Liu Apoptosis and treatment of chronic allograft nephropathy with everolimus Transplantation 76 2003 508
22. F. Giron, Y. Baez, A. Nino-Murcia Conversion therapy to everolimus in renal transplant recipientes: results after one year Transplant Proc 40 2008 711
23. V. Bumbea, N. Kamar, D. Ribes Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus Nephrol Dial Transplant 20 2005 2517
24. E. Letavernier, P. Bruneval, C. Mandet High sirolimus levels may induce focal segmental glomerulosclerosis de novo Clin J Am Soc Nephrol 2 2007 326
25. J. Pascual, I.N. Boletis, J.M. Campistol Everolimus (Certican®) in renal transplantation: a review of clinical trial data, current usage and future directions Transplant Rev 20 2006 1
26. B.L. Kasiske, A. de Mattos, S.M. Flechner Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients Am J Transplant 8 2008 1384
27. J.C. Ruiz, A. Sanchez-Fructuoso, E. Rodrigo Conversion to everolimus in kidney transplant recipientes: a safe and simple procedure Transplant Proc 38 2006 2424
28. J. Otton, C.S. Hayward, A.M. Keogh Everolimus-associated pneumonitis in three heart transplant recipients J Heart Lung Transplant 28 2009 104
29. A.V. Mulay, N. Hussain, D. Fergusson Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials Am J Transplant 5 2005 1748
30. J. Seckinger, C. Sommerer, U.P. Hinkel Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients J Hypertens 26 2008 2213